KU-55933 (ATM Kinase Inhibitor)

For research use only.

Catalog No.S1092

179 publications

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
USD 947 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's KU-55933 (ATM Kinase Inhibitor) has been cited by 179 publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 NWPOe2ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP2XJR6UUN3ME2zMlI4OzV{IN88US=> NWPoZmFDW0GQR1XS
HuO-3N1 NGPkOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXBTWM2OD12LkG3NVQzKM7:TR?= Moe4V2FPT0WU
LAMA-84 NHzEbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXvTWM2OD12LkW4OFY2KM7:TR?= MXjTRW5ITVJ?
CAL-72 NVfZNIZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPhO2dKSzVyPUWuOFgxQDRizszN MYTTRW5ITVJ?
LoVo M1PmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojqTWM2OD14LkmzNlM6KM7:TR?= NIjMPWNUSU6JRWK=
HH MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\1TWM2OD16LkK3OlcyKM7:TR?= MUPTRW5ITVJ?
SK-MEL-3 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRThwMki1O|Uh|ryP M37wUnNCVkeHUh?=
KM12 M2rxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXONVBKSzVyPUmuNlEyPDJizszN NIHtVYdUSU6JRWK=
NCI-H1437 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z5UWlEPTB;OT64NFk4KM7:TR?= NEjZRoJUSU6JRWK=
NCI-H1838 NHnRd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\McmlEPTB;MUGuNVg3PSEQvF2= MUnTRW5ITVJ?
J-RT3-T3-5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\hcGlEPTB;MUGuNlQyPyEQvF2= M1j0PHNCVkeHUh?=
GOTO M17FV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFzLk[5PVYh|ryP M4nEU3NCVkeHUh?=
LB2241-RCC NXq0THQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPVTWM2OD1zMT63NVg3KM7:TR?= M4XBVnNCVkeHUh?=
ES7 NFXKb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjldVBKSzVyPUGxMlc5QCEQvF2= MXLTRW5ITVJ?
KP-N-YS M3jwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H3[GlEPTB;MUKuOlM2PCEQvF2= MmjLV2FPT0WU
CAL-12T NEL4XHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DSOWlEPTB;MUOuOlE4KM7:TR?= MljQV2FPT0WU
COLO-684 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDwT2l{UUN3ME2xOE4yPTZ7IN88US=> MlnnV2FPT0WU
DOK NWD5SWVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULqNZFMUUN3ME2xOU4{OzJ7IN88US=> NHjqTHJUSU6JRWK=
Hs-578-T M4HuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrhV3E1UUN3ME2xOU41OTh{IN88US=> NFnMOodUSU6JRWK=
D-423MG Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fWXGlEPTB;MUWuOVI{PiEQvF2= NXPwWYpEW0GQR1XS
DBTRG-05MG MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDHUVB1UUN3ME2xOU43OTFzIN88US=> NV7uUmxSW0GQR1XS
VM-CUB-1 NFzaRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[2OGlEPTB;MUWuPVg1QSEQvF2= MYDTRW5ITVJ?
KG-1 NHPZUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle4TWM2OD1zNj6wPVk3KM7:TR?= NF\vfYtUSU6JRWK=
8305C NXm2RoRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHweGJXUUN3ME2xOk4yQDh7IN88US=> NGXUWHpUSU6JRWK=
HuH-7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6xVIxKSzVyPUG2MlI3PzRizszN MYnTRW5ITVJ?
LXF-289 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LqSmlEPTB;MU[uNlc1PyEQvF2= MlLPV2FPT0WU
NCI-H1793 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF4LkS3NVIh|ryP MXXTRW5ITVJ?
ChaGo-K-1 NVy0bJlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF4Lk[1Olgh|ryP NIrtRnlUSU6JRWK=
GCIY MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF4Lke5NFUh|ryP M4rybHNCVkeHUh?=
SK-MEL-28 M{L2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTyTWM2OD1zNz6wOFc2KM7:TR?= MYfTRW5ITVJ?
NCI-SNU-1 M3HYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHqTWM2OD1zNz6xNlY6KM7:TR?= MVnTRW5ITVJ?
CTB-1 Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF5LkKyOVkh|ryP M{DIVHNCVkeHUh?=
NCI-H82 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrPTWM2OD1zNz60OVc{KM7:TR?= NFzme2RUSU6JRWK=
HCC2998 NVrMXW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD1Umg{UUN3ME2xO{43PzN|IN88US=> Mk\wV2FPT0WU
NCI-H2030 NFrnZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF6LkG5PVch|ryP NYjyNZRuW0GQR1XS
HuP-T3 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G3NmlEPTB;MUiuOVg5QCEQvF2= Mo\vV2FPT0WU
697 NGfYeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF7LkCyNFEh|ryP NXvlNYdRW0GQR1XS
MLMA MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF7LkC1OVch|ryP MWfTRW5ITVJ?
HCC70 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF7LkS4PUDPxE1? M4LOWnNCVkeHUh?=
A704 M2PvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDuWYdKSzVyPUG5Mlg{ODVizszN NUmyT4pIW0GQR1XS
D-283MED MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDBTWM2OD1{MD61N|M6KM7:TR?= NHjY[lRUSU6JRWK=
U031 M{j6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz0Oo5KSzVyPUKxMlE1QDlizszN NFPDcFVUSU6JRWK=
HSC-3 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DvSGlEPTB;MkGuNVg{PSEQvF2= NH\2dGNUSU6JRWK=
JVM-3 M3;BOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y4cWlEPTB;MkKuOVA3KM7:TR?= MXHTRW5ITVJ?
Mewo MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEizS3lKSzVyPUKyMlUxPzNizszN NFOxNJlUSU6JRWK=
YH-13 NIXnem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:xV5BKSzVyPUKyMlUyOjNizszN MWfTRW5ITVJ?
LB1047-RCC NFjlTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXpb4NpUUN3ME2yNk42QDd7IN88US=> NX\pOIJxW0GQR1XS
HCC2157 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL4SFVQUUN3ME2yNk45ODV2IN88US=> MofYV2FPT0WU
SNU-449 NX;iTmsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnroTWM2OD1{Mj64O|Q5KM7:TR?= NV[5NVJTW0GQR1XS
Ramos-2G6-4C10 M{nHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ{Lkm2JO69VQ>? M4LJfXNCVkeHUh?=
CHL-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvoenlHUUN3ME2yN{44Ojl{IN88US=> MXzTRW5ITVJ?
SK-MEL-30 M2LUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vqRWlEPTB;MkSuOFY3OiEQvF2= NHviUG9USU6JRWK=
PANC-08-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjBOYRKSzVyPUK1MlA6OzhizszN MXLTRW5ITVJ?
QIMR-WIL NI\5SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLXPWVCUUN3ME2yOU4yQDV6IN88US=> M3zwOnNCVkeHUh?=
BFTC-905 M4TFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ3LkW5OFQh|ryP M2jaXnNCVkeHUh?=
GI-1 NVGyS|FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ3LkewOVUh|ryP NWrw[Go5W0GQR1XS
MDA-MB-415 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPrTWM2OD1{Nj61NFM{KM7:TR?= MnrzV2FPT0WU
GT3TKB Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LrTGlEPTB;Mk[uOVM1OiEQvF2= MYjTRW5ITVJ?
DEL NVL5eZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHHTWM2OD1{Nj64N|U3KM7:TR?= MlqyV2FPT0WU
KOSC-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrETWM2OD1{Nj65NFc2KM7:TR?= MXfTRW5ITVJ?
RVH-421 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ5LkK5NlEh|ryP M1TQWHNCVkeHUh?=
EW-13 M1zSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPKTWM2OD1{Nz60N|A5KM7:TR?= MnTTV2FPT0WU
639-V M1T6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHwTotrUUN3ME2yO{42OTF7IN88US=> NF3ZOFJUSU6JRWK=
A2780 NE\WZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCyTWM2OD1{Nz62OFEh|ryP MXrTRW5ITVJ?
SW982 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfTZpJKSzVyPUK3MlkxPTJizszN NXPEWGJWW0GQR1XS
SW1710 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDSNIxKSzVyPUK4MlA6QDFizszN MXrTRW5ITVJ?
HCC1569 M2PDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XqUmlEPTB;MkiuOFg6PyEQvF2= M2\SXXNCVkeHUh?=
MV-4-11 NYW3Z5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXSXYxxUUN3ME2yPE42PzN3IN88US=> M1vkT3NCVkeHUh?=
BHT-101 NUTtfYVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHzfoQ2UUN3ME2yPE43PTd{IN88US=> M4TtcnNCVkeHUh?=
Ca9-22 NYH3RXpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHXTWM2OD1{OD63NVQh|ryP NEj3bWtUSU6JRWK=
HAL-01 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe1d|B5UUN3ME2yPE44PjF3IN88US=> NX6wc4trW0GQR1XS
D-263MG M{TmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ7LkO0OEDPxE1? Ml\XV2FPT0WU
NEC8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3sXFdKSzVyPUK5MlU2PDhizszN M1zO[nNCVkeHUh?=
EKVX M2K3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLsSWhqUUN3ME2zNU42QDR5IN88US=> MlfsV2FPT0WU
EM-2 NHL2N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonyTWM2OD1|MT62N|A1KM7:TR?= NEe1TnhUSU6JRWK=
MFM-223 M4rxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHBTWM2OD1|MT64NFk5KM7:TR?= MmPVV2FPT0WU
SK-PN-DW Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVqzcFVqUUN3ME2zNk4yPDB4IN88US=> NXHVVW1lW0GQR1XS
HuO9 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjDSGtKSzVyPUOyMlUzQDJizszN NF3KUZpUSU6JRWK=
MHH-PREB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTOVHFKSzVyPUOyMlYzOzRizszN M1vlXHNCVkeHUh?=
OVCAR-4 M1jENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T2cWlEPTB;M{KuPFM3OyEQvF2= NXT2WnU5W0GQR1XS
NCI-H1648 M{iwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X3UGlEPTB;M{KuPFY2OSEQvF2= NXvIWYR5W0GQR1XS
MKN1 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLwbpYxUUN3ME2zOE4yOTBzIN88US=> M4X0V3NCVkeHUh?=
KYSE-450 M4fPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vVTmlEPTB;M{SuOlQ1PCEQvF2= NIjlSWdUSU6JRWK=
ES8 NXXFOox4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwTWM2OD1|ND64PVc2KM7:TR?= NE\ycYJUSU6JRWK=
MS-1 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ToU2lEPTB;M{SuPVU2PCEQvF2= MVXTRW5ITVJ?
HOP-92 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXnWWdVUUN3ME2zOU46Ojd5IN88US=> NEjGe|lUSU6JRWK=
SKG-IIIa NGjvdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:z[2lEPTB;M{[uNlU3OSEQvF2= NFjVXHpUSU6JRWK=
TE-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN4LkWyOFMh|ryP MljjV2FPT0WU
SK-NEP-1 NVPLd|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTN5Lk[3OFQh|ryP MYjTRW5ITVJ?
DB MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;DcoRKSzVyPUO3MlkyQDVizszN NITRW4FUSU6JRWK=
IA-LM NWLpbFE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLaTWM2OD1|OD6wNlM6KM7:TR?= MoP1V2FPT0WU
COLO-829 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nMVGlEPTB;M{iuOFE2QSEQvF2= M1Lid3NCVkeHUh?=
TGBC11TKB Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXKTWM2OD1|OT6xOFA5KM7:TR?= NVyyZpNHW0GQR1XS
CAL-51 M1zpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XO[GlEPTB;NECuNFYyOiEQvF2= M3rUUnNCVkeHUh?=
NCI-H2228 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e2SmlEPTB;NECuN|Y3OiEQvF2= M17vUHNCVkeHUh?=
C32 M{nHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDuSGFNUUN3ME20NE41ODJ2IN88US=> MVjTRW5ITVJ?
KU-19-19 M3LiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTRyLke2PFMh|ryP MYTTRW5ITVJ?
KNS-62 M1XvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDiTWM2OD12MD64N|gyKM7:TR?= M3Ky[HNCVkeHUh?=
FADU NIS0VHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHFTWM2OD12MT6yOVAzKM7:TR?= M4XmOnNCVkeHUh?=
CAL-33 NIXQUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P0NWlEPTB;NEKuOlc1QSEQvF2= NWfxdnBQW0GQR1XS
CHP-134 NGjKcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO3eGxlUUN3ME20Nk45PDl4IN88US=> NXXMS4tmW0GQR1XS
HDLM-2 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKyNoxKSzVyPUSyMlkxQDRizszN MknVV2FPT0WU
NBsusSR NF;0Z5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR|LkC3NlUh|ryP MorrV2FPT0WU
SW954 NGjkOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\VXWlEPTB;NEOuNVA2OyEQvF2= M3;3WXNCVkeHUh?=
HCC1806 NUfKdHVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jVUWlEPTB;NEOuOFEyKM7:TR?= M3vtN3NCVkeHUh?=
VMRC-RCZ NXu2S25xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fSVmlEPTB;NEOuOFU5PiEQvF2= NVPmfHdDW0GQR1XS
A549 NEWxSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO1XYtKSzVyPUSzMlk{OSEQvF2= NUTBTpExW0GQR1XS
NKM-1 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6zNYlKSzVyPUSzMlk2PThizszN M2fSb3NCVkeHUh?=
DMS-273 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn5TWM2OD12ND63OVY4KM7:TR?= MWTTRW5ITVJ?
TYK-nu M1HCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nuSmlEPTB;NEWuNVI{PCEQvF2= M37qUnNCVkeHUh?=
KALS-1 NF7hcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHLOFZKSzVyPUS1MlE1PiEQvF2= Mm[2V2FPT0WU
A101D MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;4TWM2OD12NT60OFU3KM7:TR?= MYrTRW5ITVJ?
G-361 NH;4PIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDTTWM2OD12Nj6yNVM5KM7:TR?= MlnlV2FPT0WU
KARPAS-299 NEi3WGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW2TWM2OD12Nj6zOVE3KM7:TR?= MnfLV2FPT0WU
RS4-11 M4\mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR4LkW0NkDPxE1? MVPTRW5ITVJ?
HT-1376 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PtS2lEPTB;NE[uO|QzPiEQvF2= MULTRW5ITVJ?
SK-N-AS NHvOVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfwTWM2OD12Nj63PFIzKM7:TR?= NUTReZlkW0GQR1XS
MG-63 NWT1W482T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfvTWM2OD12Nj65NFM3KM7:TR?= Mn\1V2FPT0WU
EPLC-272H M1q2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[wR4JzUUN3ME20Ok46PTB|IN88US=> NFnV[XRUSU6JRWK=
BALL-1 NX3VU|dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTR5LkizNkDPxE1? NV;yVWdyW0GQR1XS
LCLC-97TM1 M2nW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXwN28{UUN3ME20PE4zODJizszN NI\ofINUSU6JRWK=
HO-1-N-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTR6Lkm2O|Yh|ryP NGLMWoNUSU6JRWK=
MFE-280 NEH4bIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULxRVZWUUN3ME20PU41PjF5IN88US=> NUTDWWJ3W0GQR1XS
NCI-H526 NF2yUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTR7LkixOlMh|ryP NG\hdnFUSU6JRWK=
D-566MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR7LkmwPVYh|ryP MnW2V2FPT0WU
BB30-HNC NIi1fVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3TTWM2OD12OT65OFk5KM7:TR?= M3TFeHNCVkeHUh?=
SK-N-DZ MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXYTWM2OD13MD6wOFgyKM7:TR?= MXfTRW5ITVJ?
HepG2  MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu1Z|EyOMLizszN M3fkR|I1KGh? MXTicI9kc3NiU1OtTWlKOy2rbnT1Z4VlKFNicHjhd4Uh[XK{ZYP0 NWjnVYNKOjV3MkexNlM>
HepG2  MWXGeY5kfGmxbjDBd5NigQ>? MYCxNOKh|ryP MkW1NlQhcA>? M1HUepN2eHC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdnNib3[gRXROKG:wIGPldlE6QDFuIFPob|Ehd25iU3XyN|Q2NCCFaHuyJI9vKFSqck[4MEBidmRiQ3TrNkBwdiCWeYKxOUBqdmS3Y3XkJIJ6KFOFLVnJTVM> NUfTNWhyOjV3MkexNlM>
KATO III  NIXiVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS2Nk42NzVxNz61JO69VQ>? NFzzVIRFVVOR Mke1[Y5p[W6lZYOgeIhmKHSxeHnjbZR6KG:oIH;sZZBiemmk MUeyOFg1OTdzOB?=
hTCEpi MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LTfVExKM7:TR?= NHXKNJpFVVOR NHK1ZY1xemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF? MkHONlQ{PzB6M{W=
MCF10A NH3MfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm0cVEyOCEQvF2= M2XSflI1KGh? M37id2ROW09? MVXwc5RmdnSrYYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKEeD Ml\SNlQyPTB3OUW=
HL-60  NF3IZXVHfW6ldHnvckBCe3OjeR?= MnTINVAh|ryP NYPVd2JDOC53IHi= NXTaZVlmTE2VTx?= NX\GdIxLemWmdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMtMg MWGyN|k{PDRzMR?=
MCF-7 NFriZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxMVExOM7:TR?= NIjaSoMzPCCq M1rnPGZDWw>? NXfsfXBScW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= MXqyN|E5PTN2Nx?=
HeLa  MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\vT|EuOTByzszN MUmyOEBp NGTZfYNHSlN? Mn\5bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? M1S1WVI{OTh3M{S3
SH-SY5Y NVWzPXdDTnWwY4Tpc44hSXO|YYm= NEnSeJgyOMLizszNxsA> NIeyOXYzPCCq M2PqWYlvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| M{WwU|IzPjJ5Mkm0
IMR-32 Ml;DSpVv[3Srb36gRZN{[Xl? NUTUbIw{OTEEoN88UeKh MXKyOEBp NXLs[FRLcW6qaXLpeJMh[2yrb4H1bY5wdC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCyNUO= M4PySFIzPjJ5Mkm0
A549 MY\GeY5kfGmxbjDBd5NigQ>? MmjjNVDDqM7:TdMg NV73cndvOSCq M{HwWJN2eHC{ZYPz[ZMhVmGwbz3Dc{1qdmS3Y3XkJJA2OyCjY3P1cZVt[XSrb36= MojoNlI2PTl|MkG=
T47D  NGjUWldHfW6ldHnvckBCe3OjeR?= M3Hod|IxyqCvTR?= MkTWNlQhcA>? M13a[WROW09? MVXwdoV3\W62czDJVk1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFpOvmLPuQ>? M4TmNVIyOTR2OEC1
A29 MEF M3H4NGZ2dmO2aX;uJGF{e2G7 M2\pVVExyqEQvF5CpC=> MV[xbC=> NFHlclBjdG:la4RCpJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQXv0JIF1KFOnckS3N:Kh MW[yNFA2Ozd6MR?=
MDA-MB-453  M1naV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWexTGpZPS12MDFOwG0> M3W1TlczKGh? MWHJR|UxKG:oIEGwJO69VQ>? MVmyNFA2Ozd6MR?=
PC-3 NGDPRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS1MVQxKM7:TR?= NYK3e2JpPzJiaB?= M1rwVWlEPTBib3[gNVAh|ryP Mkj2NlAxPTN5OEG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

- Collapse
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
3.95 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A
Smiles O=C1C=C(OC(=C1)C2=CC=CC3=C2SC4=CC=CC=C4S3)N5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID